The independent source for health policy research, polling, and news.
201 - 220 of 1,288 Results
Gov. Gavin Newsom signed legislation expanding paid sick leave to five days, extending bereavement leave to miscarriages and failed adoptions, and approving an eventual $25-an-hour health care minimum wage. Still, in a possible sign of national ambitions, the Democrat vetoed free condoms in schools and refused to decriminalize psychedelic mushrooms.
Monica Bertagnolli, the presidents choice to head the National Institutes of Health, appeared before a Senate committee this week. Her confirmation has been held up by Sen. Bernie Sanders (I-Vt.), who has demanded President Joe Biden work more aggressively to lower prescription drug prices.
Open enrollment for Medicare beneficiaries with private health plans began Oct. 15, to be followed Nov. 1 by open enrollment for Affordable Care Act plans. The selection for both is large often too large to be navigated easily alone. And people who choose incorrectly can end up with unaffordable medical bills. Meanwhile, those on both sides of the abortion issue are looking to Ohios November ballot measure on abortion to see whether anti-abortion forces can break their losing streak in statewide ballot questions since the overturn of Roe v. Wade in 2022.
A bitterly divided Congress managed to keep the federal government running for several more weeks, while House Republicans struggle again to choose a leader. Meanwhile, many people removed from state Medicaid rolls are not finding their way to Affordable Care Act insurance, and a major investigation by The Washington Post attributes the decline in U.S. life expectancy to more than covid-19 and opioids. Lauren Weber of The Washington Post, Victoria Knight of Axios, and Sarah Karlin-Smith of the Pink Sheet join 窪蹋勛圖厙 News chief Washington correspondent Julie Rovner to discuss these issues and more. Also this week, Rovner interviews physician-author-playwright Samuel Shem about Our Hospital, his new novel about the health workforce in the age of covid.
Pharmaceutical patents can drive up the costs of lifesaving medications. Hear what author and YouTube star John Green is doing to make tuberculosis drugs more accessible to the people who need them most.
Former President Donald Trump, whos running for another term in the White House, recently blamed drug shortages on his successor, President Joe Biden. Our findings dont align with Trumps claims; by some measures, drug shortages increased more on Trumps watch than on Bidens.
A report by the U.S. Department of Health and Human Services raises troubling questions about the use of powerful medications within Floridas child welfare system and the risk of overdoses or dangerous side effects if children are given the wrong combination of drugs.
Congress appears to be careening toward a government shutdown, as a small band of House conservatives vow to block any funding for the fiscal year that begins Oct. 1 unless they win deeper cuts to health and other domestic programs. Meanwhile, former President Donald Trump continues to roil the GOP presidential primary field, this time with comments about abortion. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat, and Tami Luhby of CNN join 窪蹋勛圖厙 News chief Washington correspondent Julie Rovner to discuss these issues and more. Also, for extra credit, the panelists suggest health policy stories they read this week they think you should read, too.
Thousands of patients with autoimmune diseases who rely on Humira, with a list price of $6,600 a month, could get financial relief from new low-cost rivals. So far, the pharmacy benefit managers that control drug prices in America have not delivered on those savings.
As covid-19 hospitalizations tick upward with fall approaching, the CDC says its time for new boosters and not only for those at highest risk of serious disease. Here are seven things you need to know.
窪蹋勛圖厙 News and California Healthline staff made the rounds on national and local media this week to discuss their stories. Heres a collection of their appearances.
Congress returns from its summer recess with a long list of tasks and only a few work days to get them done. On top of the annual spending bills needed to keep the government operating, on the list are bills to renew the global HIV/AIDS program, PEPFAR, and the community health centers program. Meanwhile, over the recess, the Biden administration released the names of the first 10 drugs selected for the Medicare price negotiation program.
The Biden administration unveiled the first 10 drugs subject to price negotiations, taking a swipe at the pharmaceutical industry. But what does it mean for patients?
A Colorado board has named five drugs it will review for affordability and potential cost caps. But patients with cystic fibrosis worry they will lose access to a life-changing therapy.
To contain the opioid crisis, health and law enforcement agencies have turned to technology to monitor doctor and patient prescription data. Experts have raised questions about how these systems work and worry about their accuracy and potential biases. Some patients and doctors say theyre being unfairly targeted.
Brand-name drug prices in the U.S. more than three times the price in other developed countries are related neither to the amount of research and development required to bring them to market nor their therapeutic value, recent research shows. Have drugmakers overplayed their hand?
A federal appeals court issued a split decision on whether the abortion pill mifepristone should remain on the market rejecting a lower courts decision to effectively cancel the drugs FDA approval in 2000, while ordering the rollback of more recent rules that made the drug easier to obtain. Nothing changes immediately, however, as the Supreme Court blocked the lower courts ruling in the spring. It will be up to the high court to determine whether the pill remains available in the U.S. and under which conditions. Sarah Karlin-Smith of the Pink Sheet, Alice Miranda Ollstein of Politico, and Shefali Luthra of The 19th join 窪蹋勛圖厙 News chief Washington correspondent, Julie Rovner, to discuss these issues and more. Plus, for extra credit, the panelists suggest health policy stories they read this week they think you should read, too.
窪蹋勛圖厙 News and California Healthline staff made the rounds on national and local media this week to discuss their stories. Heres a collection of their appearances.
PBS NewsHour featured 窪蹋勛圖厙 News Aneri Pattani as it reported on how this debate is playing out in North Carolina and Ohio.
Clinics serving Alzheimers patients are working out the details of who will get treated with the new drug Leqembi. It wont be for everyone with memory-loss symptoms.
穢 2026 KFF